HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.

Abstract
Clopidogrel response varies according to the presence of genetic polymorphisms. The CYP2C19*2 allele has been associated with impaired response; conflicting results have been reported for CYP2C19*17, ABCB1, and PON1 genotypes. We assessed the impact of CYP2C19, PON1, and ABCB1 polymorphisms on clopidogrel and prasugrel pharmacodynamic (PD) and pharmacokinetic (PK) parameters. Aspirin-treated patients (N=194) with coronary artery disease from two independent, prospective, randomised, multi-centre studies comparing clopidogrel (75 mg) and prasugrel (10 mg) were genotyped and classified by predicted CYP2C19 metaboliser phenotype (ultra metabolisers [UM] = *17 carriers; extensive metabolisers [EM] = *1/1 homozygotes; reduced metabolisers [RM] = *2 carriers). ABCB1 T/T and C/T polymorphisms and PON1 A/A, A/G and G/G polymorphisms were also genotyped. PD parameters were assessed using VerifyNow® P2Y12 and vasodilator stimulated phosphoprotein (VASP) expressed as platelet reactivity index (PRI) after 14 days of maintenance dosing. Clopidogrel and prasugrel active metabolite (AM) exposure was calculated in a cohort of 96 patients. For clopidogrel, genetic variants in CYP2C19, but not ABCB1 or PON1, affected PK and PD. For prasugrel, none of the measured genetic variants affected PK or PD. Compared with clopidogrel, platelet inhibition with prasugrel was greater even in the CYP2C19 UM phenotype. Prasugrel generated more AM and achieved greater platelet inhibition than clopidogrel irrespective of CYP2C19, ABCB1, and PON1 polymorphisms. The lack of effect from genetic variants on prasugrel AM generation or antiplatelet activity is consistent with previous studies in healthy volunteers and is consistent with improved efficacy in acute coronary syndrome patients managed with percutaneous coronary intervention.
AuthorsOscar Ö Braun, Dominick J Angiolillo, Jose L Ferreiro, Joseph A Jakubowski, Kenneth J Winters, Mark B Effron, Suman Duvvuru, Timothy M Costigan, Scott Sundseth, Joseph R Walker, Jorge F Saucedo, Neal S Kleiman, Christoph Varenhorst
JournalThrombosis and haemostasis (Thromb Haemost) Vol. 110 Issue 6 Pg. 1223-31 (Dec 2013) ISSN: 2567-689X [Electronic] Germany
PMID24009042 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • ABCB1 protein, human
  • ATP Binding Cassette Transporter, Subfamily B
  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Cell Adhesion Molecules
  • Microfilament Proteins
  • P2RY12 protein, human
  • Phosphoproteins
  • Piperazines
  • Pyridines
  • Receptors, Purinergic P2Y12
  • Thiophenes
  • thienopyridine
  • vasodilator-stimulated phosphoprotein
  • Clopidogrel
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Aryldialkylphosphatase
  • PON1 protein, human
  • Prasugrel Hydrochloride
  • Ticlopidine
Topics
  • ATP Binding Cassette Transporter, Subfamily B
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 (genetics, metabolism)
  • Aged
  • Alleles
  • Aryl Hydrocarbon Hydroxylases (genetics, metabolism)
  • Aryldialkylphosphatase (genetics, metabolism)
  • Biotransformation (genetics)
  • Blood Platelets (drug effects, physiology)
  • Cell Adhesion Molecules (metabolism)
  • Cells, Cultured
  • Clopidogrel
  • Coronary Artery Disease (drug therapy, genetics)
  • Cytochrome P-450 CYP2C19
  • Female
  • Humans
  • Male
  • Microfilament Proteins (metabolism)
  • Middle Aged
  • Phosphoproteins (metabolism)
  • Piperazines (administration & dosage)
  • Platelet Activation (drug effects)
  • Polymorphism, Genetic
  • Prasugrel Hydrochloride
  • Prospective Studies
  • Pyridines (metabolism)
  • Receptors, Purinergic P2Y12 (metabolism)
  • Thiophenes (administration & dosage)
  • Ticlopidine (administration & dosage, analogs & derivatives)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: